Nambiar Indu
BHSc (Home Science), Post Graduate Dietetics, Registered Dietician, Mumbai, India.
Perspect Clin Res. 2018 Apr-Jun;9(2):103-106. doi: 10.4103/picr.PICR_52_18.
One of the reasons that a research molecule undergoes through different phases of clinical trials is to establish the safety and efficacy of the drug. To establish the safety profile of any drug, the most important aspect is to evaluate every adverse event (AE) that a clinical trial individual experiences. This detail is provided by any investigator or sponsor through the narratives that is prepared post the analysis of a serious AE. The purpose of this article is to emphasize the importance of these narratives.
研究分子要经历不同阶段临床试验的原因之一是确定药物的安全性和有效性。为了确定任何药物的安全性概况,最重要的方面是评估临床试验个体经历的每一个不良事件(AE)。任何研究者或申办者都会通过对严重不良事件进行分析后编写的叙述来提供这一细节。本文的目的是强调这些叙述的重要性。